Newsroom

Download PDF – Data Presented at the ASCO 2021 GU Cancers Symposium – –Sequencing Data Support Tivozanib is a Differentiated Selective VEGF TKI; Q-TWiST Quality of Life Measure Shows Significant Improvement for Tivozanib over Sorafenib – BOSTON, Mass.–(BUSINESS WIRE)–Feb. 11, 2021– AVEO Oncology (Nasdaq: AVEO) today announced the presentation of two analyses of the Company’s pivotal TIVO-3

Download PDF – $20M Tranche Available on Approval of Tivozanib – BOSTON–(BUSINESS WIRE)–Jan. 20, 2021– AVEO Oncology (Nasdaq: AVEO) today announced that it has received a commitment letter for an incremental $10 million loan from Hercules Capital, Inc. (NYSE: HTGC, “Hercules”) and its affiliates, to be added to the current tranched, $35 million debt facility secured with Hercules in August 2020 through an amendment to the amended

Download PDF – Data Presented at the 2021 ASCO GI Cancers Symposium – BOSTON–(BUSINESS WIRE)–Jan. 15, 2021– AVEO Oncology (Nasdaq: AVEO) today announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib (FOTIVDA®), AVEO’s vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI) drug candidate, in combination

Download PDF – Commercial Readiness Nearing Completion in Support of Potential Tivozanib U.S. Launch – – Updated IP Strategy Offers Potential for Tivozanib Patent Term Extension to November 2028 – – Corinne D. Epperly, MD, MPH, Appointed to Board of Directors – – Phase 2 Open Label Randomized Study of Ficlatuzumab in HNSCC Enrollment Complete; Plans to Announce Results and Phase 3

Download PDF BOSTON–(BUSINESS WIRE)–Jan. 6, 2021– AVEO Oncology (Nasdaq: AVEO) todayannounced that Michael Bailey, president and chief executive officer of AVEO, will participate in two upcoming virtual investor conferences: H.C. Wainwright Virtual BioConnect ConferenceDate: Monday, January 11 – Thursday, January 14 B. Riley Virtual Oncology Investor ConferenceDate: Wednesday, January 20Time: 1:30 PM Eastern Time A replay of the pre-recorded H.C. Wainwright presentation can be

Download PDF BOSTON, Mass.–(BUSINESS WIRE)–Jan. 5, 2021– AVEO Oncology (Nasdaq: AVEO) todayannounced that Michael Bailey, president and chief executive officer of AVEO, will present at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 5:20 p.m. Eastern Time. Following the presentation, Mr. Bailey will be joined by other members of AVEO’s management team for a question-and-answer session. A live webcast of the

Download PDF BOSTON–(BUSINESS WIRE)–Nov. 10, 2020– AVEO Oncology (Nasdaq: AVEO) todayannounced that Michael Bailey, president and chief executive officer of AVEO, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20 a.m. Eastern Time. A live webcast of the presentation can be accessed by visiting the investors section of the Company’s website at www.aveooncology.com. A replay of the

Download PDF – U.S. Commercial Launch Preparations Underway Supporting the Tivozanib PDUFA Target Action Date of March 31, 2021 – – Ficlatuzumab Worldwide Rights Regained; Final Results from Open Label Randomized Phase 2 HNSCC Study and Plans for Pivotal Program Expected in the Middle of 2021 – – AV-380 IND Submission Expected by Year-end; Phase 1 Clinical Study Planned for